Schwab Charles Investment Management Inc. lifted its stake in shares of Radius Health Inc (NASDAQ:RDUS) by 28.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 180,901 shares of the biopharmaceutical company’s stock after purchasing an additional 40,006 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.41% of Radius Health worth $6,974,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the company. American International Group Inc. lifted its position in shares of Radius Health by 8.1% during the third quarter. American International Group Inc. now owns 24,949 shares of the biopharmaceutical company’s stock worth $962,000 after purchasing an additional 1,866 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in shares of Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after purchasing an additional 1,044,615 shares in the last quarter. ING Groep NV acquired a new position in shares of Radius Health during the third quarter worth approximately $2,236,000. Russell Investments Group Ltd. lifted its position in shares of Radius Health by 50.6% during the third quarter. Russell Investments Group Ltd. now owns 18,916 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 6,354 shares in the last quarter. Finally, Sector Gamma AS acquired a new position in shares of Radius Health during the third quarter worth approximately $1,510,000.
Shares of Radius Health Inc (NASDAQ RDUS) opened at $34.70 on Friday. The firm has a market cap of $1,577.21, a P/E ratio of -6.39 and a beta of 1.10. Radius Health Inc has a 12 month low of $24.66 and a 12 month high of $49.16. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the business posted ($1.07) EPS. analysts predict that Radius Health Inc will post -5.57 EPS for the current year.
RDUS has been the topic of a number of research reports. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Jefferies Group reduced their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 3rd. BidaskClub upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Citigroup began coverage on shares of Radius Health in a research report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $48.00.
In related news, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction that occurred on Wednesday, October 25th. The shares were purchased at an average price of $32.85 per share, for a total transaction of $1,642,500.00. Following the completion of the transaction, the insider now owns 5,548,799 shares in the company, valued at approximately $182,278,047.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jesper Hoiland acquired 6,800 shares of Radius Health stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the transaction, the insider now owns 12,900 shares of the company’s stock, valued at approximately $374,616. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 158,578 shares of company stock worth $4,659,916. 15.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/schwab-charles-investment-management-inc-has-6-97-million-holdings-in-radius-health-inc-rdus.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.